Human Organoids Market by Offering (Models, Service), Type (Liver, Kidney, Heart), Culture Type (ECM, Suspension), Source (ASCs, ESCs), Disease Area (Oncology, GI, Neurology), Application (Screening, Toxicity, Efficacy), End User - Global Forecast to 2031

Market Size
$0.29B
MARKET SIZE, 2026
Projected Market Size
$0.90B
MARKET SIZE, 2031
CAGR
25.6%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

HUMAN ORGANOIDS MARKET SIZE, SHARE & GROWTH SNAPSHOT

human-liver-model-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global human organoids market is projected to grow from USD 0.29 billion in 2026 to USD 0.90 billion by 2031, at a CAGR of 25.6% during the forecast period. The market was valued at USD 0.21 billion in 2025. The global human organoids market encompasses finished human organoid models and services used in medical research and pharmaceutical and biotechnology development. The market includes organoid models supplied as end products, custom organoid model development services, and organoid-based in vitro testing services. These offerings support disease modeling, drug discovery and screening, efficacy and toxicity assessment, and personalized medicine research. Models representing healthy and diseased human tissues enable researchers to investigate biological mechanisms and evaluate treatment responses in a human-relevant experimental setting.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Base Year Market Size (2025): USD 0.21 Billion
    Current Market Size (2026): USD 0.29 Billion
    Forecast Market Size (2031): USD 0.90 Billion
    CAGR (2026–2031): 25.6%
  • SEGMENT LEADERSHIP:
    Regional Leader: North America accounted for the largest market share of 40.8% in 2025.
    Offering Leader: Services accounted for the largest market share of approximately 89% in 2025.
    Disease Area Leader: Oncology accounted for the largest market share of 41.8% in 2025.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    Merck (Germany), Danaher Corporation (US), and Evotec (Germany) are relevant participants through their capabilities in organoid model development, supply, expansion, and testing. Merck operates through HUB Organoids, while Danaher offers organoid solutions through Molecular Devices.
    DefiniGEN (UK) and OrganoidSciences (South Korea) are specialist companies with relevant organoid offerings. DefiniGEN supplies human intestinal organoid models, while OrganoidSciences offers organoid-based drug evaluation solutions.

The global human organoids market is expanding, supported by increasing demand for human-relevant research models, advances in stem cell technologies, and growing adoption of organoids in drug discovery, safety testing, disease modeling, and personalized medicine. The market encompasses finished organoid models and services for model development and organoid-based testing.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The global human organoids market is expanding, driven by growing demand for human-relevant experimental models, increasing adoption of organoids in pharmaceutical and biotechnology research, and advances in stem cell differentiation and three-dimensional culture techniques. Ready-to-use and customizable organoid models, together with model development and organoid-based testing services, support drug discovery and screening, toxicity and safety testing, disease modeling, and personalized medicine research. Patient-derived tumor organoids enable evaluation of anticancer drug responses and resistance mechanisms, while models of healthy and diseased tissues extend applications across gastrointestinal, liver, neurological, and other disorders. The market is also being shaped by scalable organoid production, improved model characterization, and integration into automated screening workflows. These developments support more reproducible experiments and broader use of human organoids in preclinical research, alongside efforts to reduce reliance on animal testing.

human-liver-model-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Growing demand for human-relevant drug testing and non-animal evidence
  • Expansion of standardized organoid supply and outsourced testing capacity
RESTRAINTS
Impact
Level
  • High model establishment costs and lengthy experimental turnaround
OPPORTUNITIES
Impact
Level
  • Patient-linked organoid screening for functional precision oncology
  • Expansion into immune and non-oncology organoid applications
CHALLENGES
Impact
Level
  • Reproducibility and fit-for-purpose predictive validation

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing demand for human-relevant drug testing and non-animal evidence

Increasing demand for models that better reflect human biology is supporting adoption of organoids for drug screening and safety assessment. Regulatory encouragement of scientifically validated non-animal methods is creating further demand for organoid models and testing services.

Restraint: High model establishment costs and lengthy experimental turnaround

Specialized personnel, culture optimization, expansion, and quality-control requirements increase the resources needed to establish organoid models. Variable establishment success and lengthy development and screening workflows can delay results, limiting adoption in research programs with constrained budgets or time-sensitive treatment decisions.

Opportunity: Patient-linked organoid screening for functional precision oncology

Linking patient-derived tumor organoid drug responses with clinical and molecular information creates opportunities for personalized treatment research. Testing individual drug sensitivities and combinations can complement genomic profiling, supporting development of screening services and prospective studies of treatment-response prediction.

Challenge: Reproducibility and fit-for-purpose predictive validation

Differences in sample quality, culture conditions, and assay methods can affect organoid establishment and drug-response results. Suppliers must demonstrate consistent performance and validate each model for its intended application, using appropriate reference data and endpoints to establish confidence in its predictive value.

HUMAN ORGANOIDS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
AstraZeneca researchers acquired an adult stem cell-derived human small intestinal organoid model from the HUB biobank. They used it to evaluate toxicity associated with oral oncology drugs. Organoid response data were integrated into mathematical models to predict intestinal injury and clinical diarrhea, supporting investigation of drug dosing and schedules.
company logo
Roche (Genentech) purchased patient-derived colorectal cancer organoids PDM95, PDM96, and PDM2674 from ATCC. Provided access to established human colorectal cancer models for experimental studies, avoiding the need to derive each model from fresh patient samples.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The global human organoids market comprises an interconnected ecosystem of organoid model suppliers, specialized service providers, pharmaceutical and biotechnology companies, academic and research institutes, CROs/CRDMOs, hospitals, and clinical laboratories. Model suppliers provide ready-to-use and customizable human organoids, while service providers support model development and organoid-based testing for drug discovery, safety assessment, disease modeling, and personalized medicine research. Hospitals, tissue repositories, and biobanks facilitate access to consented patient samples and associated clinical information, enabling development of models representing healthy and diseased tissues. Academic institutions advance differentiation protocols, model characterization, and biological validation, often collaborating with commercial providers to translate research into scalable offerings. Supporting technology providers supply culture materials, automation, imaging, genomic analysis, and cryopreservation capabilities that enable organoid workflows, although these inputs remain outside the study’s revenue scope. Regulatory authorities and ethics committees guide applicable requirements for human tissue use, donor consent, data protection, and validation of testing methods. Collectively, these stakeholders improve model availability, reproducibility, and predictive relevance, supporting broader adoption of finished human organoid models and development and testing services across oncology and other medical research applications.

human-liver-model-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

human-liver-model-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Human Organoids Market, by Offering

The market covers finished organoid models and services. Ready-to-use and customizable models support experiments within customer laboratories, while model development and organoid-based testing services provide access to specialized expertise. Demand centers on reproducible models, disease-specific capabilities, and reliable research data.

Human Organoid Models Market, by Model Type

The study covers liver, intestinal & colorectal, kidney, pancreatic, lung, heart, and other organoid models. Demand reflects their use in organ-specific disease research, drug screening, and safety assessment. Tissue functionality, donor characteristics, and experimental suitability influence model selection.

Human Organoid Models Market, by Culture Type

Culture types include ECM/Matrigel-based, air–liquid interface, suspension, and other culture systems. These approaches influence organoid architecture, maturation, and scalability. Improved control of culture conditions supports consistent finished models for research and testing applications.

Human Organoid Models Market, by Source

Source coverage includes pluripotent stem cells, adult stem cells, embryonic stem cells, and other human tissue sources. Patient-derived models support investigation of individual disease characteristics, while stem cell-derived organoids enable developmental and genetic disease research. Source selection depends on the intended biological question.

Human Organoids Market, by Disease Area

The market covers oncology, liver diseases, gastrointestinal diseases, cardiovascular diseases, infectious diseases, neurological disorders, and other disease areas. Patient-derived tumor organoids support drug response and resistance studies, while other disease-specific models enable investigation of pathological mechanisms and potential treatments.

Human Organoids Market, by Application

Applications include drug discovery & screening, drug toxicity & safety testing, disease modeling, developmental biology, personalized medicine, regenerative medicine and tissue engineering, and other applications. Demand is supported by the need for human-relevant experimental systems, with adoption depending on model reproducibility and validation for the intended use.

Human Organoid Models Market, by End User

End users include pharmaceutical & biotechnology companies, academic & research institutes, CROs/CRDMOs, and other end users. Finished models support candidate evaluation, disease research, and tissue development studies. Buyers assess biological relevance, characterization, consistency, and compatibility with laboratory workflows.

Human Organoid Services Market, by End User

Service customers include pharmaceutical & biotechnology companies, academic & research institutes, CROs/CRDMOs, and other users. Outsourcing provides access to customized organoid development and specialized testing capabilities. Provider selection depends on model relevance, assay performance, turnaround time, and data quality.

Human Organoids Market, by Region

The study covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa separately. Regional opportunities depend on pharmaceutical research activity, specialist providers, research funding, and access to patient material. Standardization and validation support broader adoption of organoid models and services.

REGION

Asia Pacific to be fastest-growing region in market during forecast period

During the forecast period, Asia Pacific is expected to witness rapid growth in the human organoids market, supported by advances in stem cell research and increasing adoption of human-relevant models for drug discovery, disease modeling, and safety testing. Academic–industry collaborations and development of standardized organoid platforms are strengthening regional capabilities. Expansion of commercial model development and testing services, alongside growing interest in patient-derived screening and personalized medicine, is expected to support demand for ready-to-use and customizable organoid models across the region.

human-liver-model-market Region

HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX

In the global human organoids market, Merck is a strong candidate for the star quadrant, supported by its patient-derived organoid portfolio and model development and screening capabilities through HUB Organoids. Its offerings cover healthy and diseased tissues, with applications in oncology, toxicology, and inflammatory disease research. These capabilities, combined with its global commercial reach, strengthen its position across organoid models and services. ACROBiosystems is a candidate for the emerging leader quadrant, supported by its ready-to-use human iPSC-derived organoid models and specialized testing capabilities. Its cardiac and cerebral organoid offerings support drug screening, disease modeling, and safety assessment. Its focus on standardized models, functional characterization, and organoid-based cardiotoxicity testing positions it to address growing demand for reproducible human-relevant research solutions.

human-liver-model-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) 0.21 BN
Market Size in 2026 (Value) 0.29 BN
Market Forecast in 2031 (Value) 0.90 BN
Growth Rate 25.6%
Years Considered 2023–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD Million/Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Offering:
    • Organoid Models [Ready-to-use Organoid Models
    • Customizable Organoid Models]
    • Services [Model Development Services
    • Organoid Model-based Testing Services]
  • By Model Type:
    • Liver Models
    • Intestinal & Colorectal Models
    • Kidney Models
    • Pancreatic Models
    • Lung Models
    • Heart Models
    • Other Organoid Models
  • By Culture Type:
    • ECM/Matrigel-based Culture
    • Air–Liquid Interface
    • Suspension
    • Other Culture Types
  • By Source:
    • Pluripotent Stem Cells
    • Adult Stem Cells
    • Embryonic Stem Cells
    • Other Sources
  • By Disease Area:
    • Oncology
    • Liver Diseases/Hepatological Disorders
    • Gastrointestinal Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurological Disorders
    • Other Disease Areas
  • By Application:
    • Drug Discovery & Screening
    • Drug Toxicity & Safety Testing
    • Disease Modeling
    • Developmental Biology
    • Personalized Medicine
    • Regenerative Medicine and Tissue Engineering
    • Other Applications
  • By End User - Organoid Models:
    • Pharmaceutical and Biotech Companies
    • Academic & Research Institutes
    • CROs/CRDMOs
    • Other End Users
  • By End User - Services:
    • Pharmaceutical and Biotech Companies
    • Academic & Research Institutes
    • CROs/CRDMOs
    • Other End Users
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: HUMAN ORGANOIDS MARKET REPORT CONTENT GUIDE

human-liver-model-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Evaluate India’s 3D cell culture market, including organoids, spheroids, and organ-on-chip technologies Provided a customized evaluation of India’s 3D cell culture market covering organoids, spheroids, and organ-on-chip technologies. Assessed market potential, application-specific analysis, supplier capabilities, end-user adoption, and commercialization opportunities across pharmaceutical and biomedical research. Supports India market-entry planning, technology prioritization, identification of potential customers and partners, and development of strategies suited to local research needs.
Assess opportunities for human organoid models and outsourced research services Customized assessment of ready-to-use and customizable organoid models, model development services, and organoid-based testing services. Examines opportunities across drug screening, safety testing, disease modeling, and personalized medicine research, alongside customer requirements and supplier capabilities. Supports portfolio expansion, service differentiation, partnership development, and prioritization of applications and customer segments with strong commercial potential.

RECENT DEVELOPMENTS

  • April 2026 : Crown Bioscience (US) and Turbine announced a partnership to integrate AI-driven virtual assays with Crown Bioscience’s tumor organoid testing capabilities. Selected computational predictions will be experimentally validated using organoid assays to support oncology target identification and treatment-combination research.
  • January 2025 : Merck (Germany) announced the completion of its acquisition of HUB Organoids (Netherlands). The transaction, which closed in December 2024, expanded Merck’s capabilities in patient-derived organoids, model generation, assay development, and high-throughput screening services.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
39
2
EXECUTIVE SUMMARY
 
 
 
 
 
44
3
PREMIUM INSIGHTS
 
 
 
 
 
51
4
MARKET OVERVIEW
Unlock growth by leveraging patient-linked organoid screening and expanding into non-oncology applications.
 
 
 
 
 
55
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
GROWING DEMAND FOR HUMAN-RELEVANT DRUG TESTING AND NON-ANIMAL EVIDENCE
 
 
 
 
 
 
4.2.1.2
EXPANSION OF STANDARDIZED ORGANOID SUPPLY AND OUTSOURCED TESTING CAPACITY
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH MODEL ESTABLISHMENT COSTS AND LENGTHY EXPERIMENTAL TURNAROUND
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
PATIENT-LINKED ORGANOID SCREENING FOR FUNCTIONAL PRECISION ONCOLOGY
 
 
 
 
 
 
4.2.3.2
EXPANSION INTO IMMUNE AND NON-ONCOLOGY ORGANOID APPLICATIONS
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
REPRODUCIBILITY AND FIT-FOR-PURPOSE PREDICTIVE VALIDATION
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate competitive pressures and macroeconomic shifts shaping the global human organoids market.
 
 
 
 
 
62
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
 
5.4.1
LIST OF KEY HUMAN ORGANOID MODEL AND SERVICE PROVIDERS
 
 
 
 
 
 
5.4.2
PRODUCTION SITES AND CAPABILITY DEVELOPMENTS OF KEY ORGANOID PROVIDERS
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
AVERAGE SELLING PRICE, BY PRODUC/ SERVICE
 
 
 
 
 
5.6
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.8
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
 
 
5.9
IMPACT OF 2025 US TARIFFS—GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
 
 
5.9.1
INTRODUCTION
 
 
 
 
 
 
5.9.2
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.9.3
IMPACT ON REGIONS
 
 
 
 
 
 
 
5.9.3.1
NORTH AMERICA
 
 
 
 
 
 
5.9.3.2
EUROPE
 
 
 
 
 
 
5.9.3.3
ASIA PACIFIC
 
 
 
 
 
5.9.4
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.9.4.1
PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.9.4.2
ACADEMIC AND RESEARCH INSTITUTES
 
 
 
 
 
 
5.9.4.3
CROS/CRDMOS AND OTHER RESEARCH END USERS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize organoid technology, unlocking unprecedented market potential and future applications.
 
 
 
 
 
80
 
6.1
KEY EMERGING TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
AI-ENABLED AND DIGITAL AUTOMATED AND HIGH-THROUGHPUT ORGANOID PLATFORMS
 
 
 
 
 
6.2
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
ORGAN-ON-CHIP/MICROPHYSIOLOGICAL SYSTEMS
 
 
 
 
 
 
6.2.2
ADVANCED SPHEROID & 3D MICROTISSUE MODELS
 
 
 
 
 
6.3
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
SPATIAL TRANSCRIPTOMICS AND SPATIAL OMICS
 
 
 
 
 
 
6.3.2
CRISPR/CAS GENOME EDITING
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
TOP APPLICANTS/OWNERS (COMPANIES), FOR HUMAN ORGANOIDS PATENTS, 2015–2025
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
6.7
IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
 
 
6.7.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
 
6.7.2
CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
6.7.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
6.7.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate complex global regulations with insights into sustainability-driven policy initiatives and eco-standards.
 
 
 
 
 
88
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
 
 
 
 
 
 
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYING BEHAVIOR
Decode buyer dynamics to navigate stakeholder influence and overcome adoption barriers effectively.
 
 
 
 
 
95
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
KEY BUYING CRITERIA FOR HUMAN ORGANOID MODELS, BY END USER
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM END USERS
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
9
HUMAN ORGANOIDS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 33 Data Tables
 
 
 
 
 
101
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
ORGANOID MODELS
 
 
 
 
 
 
 
9.2.1
READY-TO-USE ORGANOID MODELS
 
 
 
 
 
 
 
9.2.1.1
INCREASING DEMAND FOR READY-TO-USE ORGANOID MODELS TO DRIVE MARKET GROWTH
 
 
 
 
 
9.2.2
CUSTOMIZABLE ORGANOID MODELS
 
 
 
 
 
 
 
9.2.2.1
RISING DEMAND FOR CUSTOMIZABLE ORGANOID MODELS TO SUPPORT MARKET GROWTH
 
 
 
 
9.3
SERVICES
 
 
 
 
 
 
 
9.3.1
MODEL DEVELOPMENT SERVICES
 
 
 
 
 
 
 
9.3.1.1
RISING DEMAND FOR CUSTOMIZED HUMAN ORGANOID MODELS TO DRIVE GROWTH OF MODEL DEVELOPMENT SERVICES
 
 
 
 
 
9.3.2
ORGANOID MODEL-BASED TESTING SERVICES
 
 
 
 
10
HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
117
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
LIVER MODELS
 
 
 
 
 
 
 
10.2.1
RISING USE OF LIVER ORGANOID MODELS IN DRUG DISCOVERY AND TOXICITY TESTING TO DRIVE MARKET GROWTH
 
 
 
 
 
10.3
INTESTINAL & COLORECTAL MODELS
 
 
 
 
 
 
 
10.3.1
RISING USE OF INTESTINAL & COLORECTAL ORGANOID MODELS IN DISEASE MODELING AND DRUG SCREENING TO DRIVE MARKET GROWTH
 
 
 
 
 
10.4
KIDNEY MODELS
 
 
 
 
 
 
 
10.4.1
RISING USE OF KIDNEY ORGANOID MODELS IN DISEASE MODELING AND DRUG TOXICITY TESTING TO DRIVE MARKET GROWTH
 
 
 
 
 
10.5
PANCREATIC MODELS
 
 
 
 
 
 
 
10.5.1
RISING USE OF PANCREATIC ORGANOID MODELS IN DISEASE MODELING AND DRUG DISCOVERY TO DRIVE MARKET GROWTH
 
 
 
 
 
10.6
LUNG MODELS
 
 
 
 
 
 
 
10.6.1
RISING USE OF LUNG ORGANOID MODELS IN DISEASE MODELING AND DRUG SCREENING TO DRIVE MARKET GROWTH
 
 
 
 
 
10.7
HEART MODELS
 
 
 
 
 
 
 
10.7.1
RISING USE OF HEART ORGANOID MODELS IN CARDIOVASCULAR RESEARCH TO DRIVE MARKET GROWTH
 
 
 
 
 
10.8
OTHER ORGANOID MODELS
 
 
 
 
 
11
HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 21 Data Tables
 
 
 
 
 
133
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
ECM/MATRIGEL-BASED CULTURE
 
 
 
 
 
 
 
11.2.1
WIDESPREAD USE OF ECM/MATRIGEL-BASED CULTURE TO DRIVE HUMAN ORGANOIDS MARKET GROWTH
 
 
 
 
 
11.3
AIR-LIQUID INTERFACE CULTURE
 
 
 
 
 
 
 
11.3.1
INCREASING ADOPTION OF AIR-LIQUID INTERFACE CULTURE TO DRIVE MARKET GROWTH
 
 
 
 
 
11.4
SUSPENSION
 
 
 
 
 
 
 
11.4.1
RISING DEMAND FOR SCALABLE ORGANOID PRODUCTION TO DRIVE MARKET GROWTH
 
 
 
 
 
11.5
OTHER CULTURE TYPES
 
 
 
 
 
12
HUMAN ORGANOIDS MODELS MARKET, BY SOURCE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 21 Data Tables
 
 
 
 
 
143
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
PLURIPOTENT STEM CELLS
 
 
 
 
 
 
 
12.2.1
EXPANDING USE OF PLURIPOTENT STEM CELLS IN TISSUE-SPECIFIC ORGANOID DEVELOPMENT TO DRIVE MARKET GROWTH
 
 
 
 
 
12.3
ADULT STEM CELLS
 
 
 
 
 
 
 
12.3.1
RISING USE OF ADULT STEM CELLS FOR PHYSIOLOGICALLY RELEVANT ORGANOID MODELS TO DRIVE MARKET GROWTH
 
 
 
 
 
12.4
EMBRYONIC STEM CELLS
 
 
 
 
 
 
 
12.4.1
INCREASING USE OF EMBRYONIC STEM CELL-DERIVED ORGANOIDS IN DEVELOPMENTAL AND DISEASE RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
 
12.5
OTHER SOURCES
 
 
 
 
 
13
HUMAN ORGANOIDS MARKET, BY DISEASE AREA
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 37 Data Tables
 
 
 
 
 
153
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
ONCOLOGY
 
 
 
 
 
 
 
13.2.1
INCREASING ADOPTION OF TUMOR ORGANOIDS FOR DISEASE MODELING AND DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
 
 
 
 
 
13.3
LIVER DISEASES/HEPATOLOGICAL DISORDERS
 
 
 
 
 
 
 
13.3.1
INCREASING ADOPTION OF LIVER ORGANOIDS FOR DISEASE MODELING AND DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
 
 
 
 
 
13.4
GASTROINTESTINAL DISEASES
 
 
 
 
 
 
 
13.4.1
WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET
 
 
 
 
 
13.5
CARDIOVASCULAR DISEASES
 
 
 
 
 
 
 
13.5.1
RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
 
 
 
 
 
13.6
INFECTIOUS DISEASES
 
 
 
 
 
 
 
13.6.1
USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH
 
 
 
 
 
13.7
NEUROLOGICAL DISORDERS
 
 
 
 
 
 
 
13.7.1
GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS
 
 
 
 
 
13.8
OTHER DISEASE AREAS
 
 
 
 
 
14
HUMAN ORGANOIDS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 36 Data Tables
 
 
 
 
 
170
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
DRUG DISCOVERY & SCREENING
 
 
 
 
 
 
 
14.2.1
RISING USE OF HUMAN ORGANOIDS IN DRUG DISCOVERY AND SCREENING TO DRIVE MARKET GROWTH
 
 
 
 
 
14.3
DRUG TOXICITY & SAFETY TESTING
 
 
 
 
 
 
 
14.3.1
RISING USE OF HUMAN ORGANOIDS FOR DRUG TOXICITY AND SAFETY TESTING TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.4
DISEASE MODELING
 
 
 
 
 
 
 
14.4.1
RISING APPLICATION OF HUMAN ORGANOIDS IN DISEASE MODELING TO DRIVE MARKET GROWTH
 
 
 
 
 
14.5
DEVELOPMENTAL BIOLOGY
 
 
 
 
 
 
 
14.5.1
INCREASING USE OF HUMAN ORGANOIDS IN DEVELOPMENTAL BIOLOGY TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.6
PERSONALIZED MEDICINE
 
 
 
 
 
 
 
14.6.1
RISING ADOPTION OF PATIENT-DERIVED ORGANOIDS FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
 
 
 
 
 
14.7
REGENERATIVE MEDICINE
 
 
 
 
 
 
 
14.7.1
EXPANDING APPLICATIONS OF HUMAN ORGANOIDS IN REGENERATIVE MEDICINE AND TISSUE ENGINEERING TO SUPPORT MARKET GROWTH
 
 
 
 
 
14.8
OTHER APPLICATIONS
 
 
 
 
 
15
HUMAN ORGANOID MODELS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 21 Data Tables
 
 
 
 
 
186
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
15.2.1
INCREASING ADOPTION OF HUMAN ORGANOID MODELS BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH
 
 
 
 
 
15.3
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
15.3.1
RISING USE OF HUMAN ORGANOIDS IN ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET GROWTH
 
 
 
 
 
15.4
CROS/CRDMOS
 
 
 
 
 
 
 
15.4.1
INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO DRIVE ADOPTION OF HUMAN ORGANOID MODELS BY CROS/CRDMOS
 
 
 
 
 
15.5
OTHER END USERS
 
 
 
 
 
16
HUMAN ORGANOID SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 21 Data Tables
 
 
 
 
 
196
 
16.1
INTRODUCTION
 
 
 
 
 
 
16.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
16.2.1
INCREASING OUTSOURCING OF ORGANOID DEVELOPMENT AND TESTING TO DRIVE MARKET GROWTH
 
 
 
 
 
16.3
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
16.3.1
RISING USE OF ORGANOID SERVICES IN ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET GROWTH
 
 
 
 
 
16.4
CROS/CRDMOS
 
 
 
 
 
 
 
16.4.1
INCREASING OUTSOURCING OF PRECLINICAL RESEARCH TO DRIVE ADOPTION OF ORGANOID SERVICES BY CROS/CRDMOS
 
 
 
 
 
16.5
OTHER END USERS
 
 
 
 
 
17
HUMAN ORGANOIDS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 14 Countries | 225 Data Tables.
 
 
 
 
 
206
 
17.1
INTRODUCTION
 
 
 
 
 
 
17.2
NORTH AMERICA
 
 
 
 
 
 
 
17.2.1
US
 
 
 
 
 
 
 
17.2.1.1
INCREASING ADOPTION OF HUMAN ORGANOIDS IN DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
 
 
 
 
 
17.2.2
CANADA
 
 
 
 
 
 
 
17.2.2.1
GROWING ORGANOID RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH IN CANADA
 
 
 
 
17.3
EUROPE
 
 
 
 
 
 
 
17.3.1
GERMANY
 
 
 
 
 
 
 
17.3.1.1
STRONG PHARMACEUTICAL AND RESEARCH ECOSYSTEM TO SUPPORT MARKET GROWTH
 
 
 
 
 
17.3.2
UK
 
 
 
 
 
 
 
17.3.2.1
INCREASING ORGANOID RESEARCH AND DRUG DISCOVERY ACTIVITIES TO DRIVE MARKET GROWTH
 
 
 
 
 
17.3.3
FRANCE
 
 
 
 
 
 
 
17.3.3.1
GROWING LIFE SCIENCES RESEARCH AND ORGANOID APPLICATIONS TO SUPPORT MARKET GROWTH
 
 
 
 
 
17.3.4
ITALY
 
 
 
 
 
 
 
17.3.4.1
EXPANDING BIOMEDICAL RESEARCH TO DRIVE ADOPTION OF HUMAN ORGANOIDS IN ITALY
 
 
 
 
 
17.3.5
SPAIN
 
 
 
 
 
 
 
17.3.5.1
RISING USE OF ORGANOIDS IN BIOMEDICAL RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
 
17.3.6
REST OF EUROPE
 
 
 
 
 
 
 
17.3.6.1
EXPANDING ORGANOID RESEARCH ACROSS EUROPEAN COUNTRIES TO SUPPORT MARKET GROWTH
 
 
 
 
17.4
ASIA PACIFIC
 
 
 
 
 
 
 
17.4.1
CHINA
 
 
 
 
 
 
 
17.4.1.1
INCREASING PHARMACEUTICAL R&D AND ORGANOID RESEARCH TO DRIVE MARKET GROWTH
 
 
 
 
 
17.4.2
JAPAN
 
 
 
 
 
 
 
17.4.2.1
ADVANCING REGENERATIVE MEDICINE AND DRUG RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
 
17.4.3
INDIA
 
 
 
 
 
 
 
17.4.3.1
EXPANDING PHARMACEUTICAL RESEARCH AND BIOTECHNOLOGY ACTIVITIES TO DRIVE MARKET GROWTH
 
 
 
 
 
17.4.4
SOUTH KOREA
 
 
 
 
 
 
 
17.4.4.1
GROWING BIOTECHNOLOGY INVESTMENTS TO SUPPORT HUMAN ORGANOID MARKET GROWTH
 
 
 
 
 
17.4.5
AUSTRALIA
 
 
 
 
 
 
 
17.4.5.1
INCREASING BIOMEDICAL RESEARCH TO SUPPORT MARKET GROWTH IN AUSTRALIA
 
 
 
 
 
17.4.6
REST OF ASIA PACIFIC
 
 
 
 
 
 
 
17.4.6.1
RISING BIOTECHNOLOGY RESEARCH AND DRUG DEVELOPMENT ACTIVITIES TO SUPPORT MARKET GROWTH
 
 
 
 
17.5
LATIN AMERICA
 
 
 
 
 
 
 
17.5.1
BRAZIL
 
 
 
 
 
 
 
17.5.1.1
GROWING BIOMEDICAL RESEARCH TO SUPPORT HUMAN ORGANOID MARKET GROWTH
 
 
 
 
 
17.5.2
MEXICO
 
 
 
 
 
 
 
17.5.2.1
EXPANDING PHARMACEUTICAL RESEARCH TO DRIVE MARKET GROWTH IN MEXICO
 
 
 
 
 
17.5.3
REST OF LATIN AMERICA
 
 
 
 
 
 
 
17.5.3.1
EXPANDING PHARMACEUTICAL RESEARCH TO DRIVE MARKET GROWTH IN MEXICO
 
 
 
 
17.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
17.6.1
GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
18
COMPETITIVE LANDSCAPE
Discover top strategies and emerging leaders revolutionizing the human organoids market landscape.
 
 
 
 
 
311
 
18.1
INTRODUCTION
 
 
 
 
 
 
18.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
18.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET
 
 
 
 
 
18.3
REVENUE ANALYSIS, 2023–2025
 
 
 
 
 
 
 
18.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
18.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
18.5.1
STARS
 
 
 
 
 
 
18.5.2
EMERGING LEADERS
 
 
 
 
 
 
18.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
18.5.4
PARTICIPANTS
 
 
 
 
 
 
18.5.5
COMPANY FOOTPRINT, KEY PLAYERS, 2025
 
 
 
 
 
 
 
18.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
18.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
18.5.5.3
OFFERING FOOTPRINT
 
 
 
 
 
 
18.5.5.4
SOURCE FOOTPRINT
 
 
 
 
 
 
18.5.5.5
APPLICATION FOOTPRINT
 
 
 
 
18.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
18.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
18.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
18.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
18.6.4
STARTING BLOCKS
 
 
 
 
 
 
18.6.5
COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2025
 
 
 
 
 
 
 
18.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
18.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
18.7
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
18.8
BRAND COMPARATIVE ANALYSIS
 
 
 
 
 
 
18.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
18.9.1
PRODUCT/ SERVICE LAUNCHES
 
 
 
 
 
 
18.9.2
DEALS
 
 
 
 
 
 
18.9.3
OTHER DEVELOPMENTS
 
 
 
 
19
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
329
 
19.1
KEY PLAYERS
 
 
 
 
 
 
 
19.1.1
MERCK KGAA
 
 
 
 
 
 
 
19.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
19.1.1.2
PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
19.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
19.1.1.3.1
DEALS
 
 
 
 
 
 
19.1.1.3.2
EXPANSIONS
 
 
 
 
19.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
19.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
19.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
19.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
19.1.2
DANAHER CORPORATION
 
 
 
 
 
 
19.1.3
SAMSUNG BIOLOGICS
 
 
 
 
 
 
19.1.4
WUXI APPTEC
 
 
 
 
 
 
19.1.5
EVOTEC SE
 
 
 
 
 
 
19.1.6
CHAMPIONS ONCOLOGY
 
 
 
 
 
 
19.1.7
ACROBIOSYSTEMS
 
 
 
 
 
 
19.1.8
BIOMORGAN LIMITED
 
 
 
 
 
 
19.1.9
ORGANOID SCIENCES, INC.
 
 
 
 
 
 
19.1.10
JSR CORPORATION
 
 
 
 
 
 
19.1.11
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
19.1.12
BRUKER CORPORATION
 
 
 
 
 
 
19.1.13
CHARLES RIVER LABORATORIES
 
 
 
 
 
 
19.1.14
PHARMARON
 
 
 
 
 
 
19.1.15
VIVOSIM LABS, INC.
 
 
 
 
 
 
19.1.16
STEMCELL TECHNOLOGIES
 
 
 
 
 
19.2
OTHER PLAYERS
 
 
 
 
 
 
 
19.2.1
SCREENIN3D
 
 
 
 
 
 
19.2.2
DISCOVERY LIFE SCIENCES
 
 
 
 
 
 
19.2.3
LIDE BIOTECH
 
 
 
 
 
 
19.2.4
INNOSER
 
 
 
 
 
 
19.2.5
CENSO BIOTECHNOLOGIES LTD
 
 
 
 
 
 
19.2.6
CREATIVE BIOLABS
 
 
 
 
 
 
19.2.7
PANDORUM TECHNOLOGIES PVT. LTD.
 
 
 
 
 
 
19.2.8
INVITROCUE
 
 
 
 
 
 
19.2.9
NEYROBLASTGX LLC
 
 
 
 
 
 
19.2.10
DEXORGEN
 
 
 
 
 
 
19.2.11
PIXLBIO
 
 
 
 
20
RESEARCH METHODOLOGY
 
 
 
 
 
382
 
20.1
RESEARCH DATA
 
 
 
 
 
 
20.2
RESEARCH APPROACH
 
 
 
 
 
 
 
20.2.1
SECONDARY DATA
 
 
 
 
 
 
 
20.2.1.1
KEY SECONDARY SOURCES
 
 
 
 
 
 
20.2.1.2
KEY DATA FROM SECONDARY RESEARCH
 
 
 
 
 
20.2.2
PRIMARY DATA
 
 
 
 
 
 
 
20.2.2.1
KEY DATA FROM PRIMARY SOURCES
 
 
 
 
 
 
20.2.2.2
BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
20.3
MARKET SIZE ESTIMATION
 
 
 
 
 
 
 
20.3.1
GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025
 
 
 
 
 
 
 
20.3.1.1
APPROACH 1: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP)
 
 
 
 
 
 
20.3.1.2
APPROACH 2: SECONDARY RESEARCH
 
 
 
 
 
 
20.3.1.3
APPROACH 3: PRIMARY RESEARCH
 
 
 
 
 
 
20.3.1.4
KEY INDUSTRY INSIGHTS
 
 
 
 
 
 
20.3.1.5
APPROACH 3: MNM REPOSITORY ANALYSIS
 
 
 
 
 
20.3.2
SEGMENTAL MARKET SIZE ESTIMATION, 2025
 
 
 
 
 
20.4
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
 
 
20.4.1
CAGR PROJECTIONS
 
 
 
 
 
20.5
DATA TRIANGULATION
 
 
 
 
 
 
20.6
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
20.7
RESEARCH LIMITATIONS
 
 
 
 
 
 
20.8
RISK ASSESSMENT
 
 
 
 
 
21
APPENDIX
 
 
 
 
 
395
 
21.1
DISCUSSION GUIDE
 
 
 
 
 
 
21.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
21.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
21.4
RELATED REPORTS
 
 
 
 
 
 
21.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
HUMAN ORGANOIDS MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
 
 
TABLE 2
HUMAN ORGANOIDS MARKET: IMPACT ANALYSIS
 
 
 
 
 
 
TABLE 3
GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 4
GLOBAL HUMAN ORGANOIDS MARKET: KEY MODEL AND SERVICE PROVIDERS
 
 
 
 
 
 
TABLE 5
GLOBAL HUMAN ORGANOIDS MARKET: PRODUCTION SITES AND CAPABILITY DEVELOPMENTS
 
 
 
 
 
 
TABLE 6
AVERAGE SELLING PRICE OF HUMAN ORGANOIDS, BY PRODUCT/ SERVICE, 2025
 
 
 
 
 
 
TABLE 7
GLOBAL HUMAN ORGANOIDS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 8
HUMAN ORGANOIDS MARKET: INDICATIVE LIST OF PATENTS, 2024–2025
 
 
 
 
 
 
TABLE 9
CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
TABLE 10
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
TABLE 11
HUMAN ORGANOIDS REGULATORY GUIDANCE/FRAMEWORK, BY OFFERING
 
 
 
 
 
 
TABLE 12
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 13
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 14
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 15
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 16
ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY MODEL TYPE (%)
 
 
 
 
 
 
TABLE 17
ILLUSTRATIVE BUYING CRITERIA, BY END USER
 
 
 
 
 
 
TABLE 18
HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 19
HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 20
HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 21
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 22
EUROPE: HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 23
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 24
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 25
READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 26
NORTH AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
EUROPE: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
LATIN AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
EUROPE: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
HUMAN ORGANOID MODEL SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
NORTH AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
EUROPE: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
ASIA PACIFIC: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
LATIN AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
NORTH AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
EUROPE: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
ASIA PACIFIC: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
LATIN AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
NORTH AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
EUROPE: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
ASIA PACIFIC: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
LATIN AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
LIVER MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
NORTH AMERICA: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
EUROPE: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
ASIA PACIFIC: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
LATIN AMERICA: LIVER MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
INTESTINAL & COLORECTAL MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
NORTH AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
EUROPE: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
ASIA PACIFIC: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
LATIN AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
KIDNEY MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
NORTH AMERICA: KIDNEY MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
EUROPE: KIDNEY MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
ASIA PACIFIC: KIDNEY MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
LATIN AMERICA: KIDNEY MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
PANCREATIC MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
NORTH AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
EUROPE: PANCREATIC MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
ASIA PACIFIC: PANCREATIC MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
LATIN AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
LUNG MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
NORTH AMERICA: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
EUROPE: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
ASIA PACIFIC: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
LATIN AMERICA: LUNG MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
HEART MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
NORTH AMERICA: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
EUROPE: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
ASIA PACIFIC: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
LATIN AMERICA: HEART MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
OTHER HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
NORTH AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
EUROPE: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
ASIA PACIFIC: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
LATIN AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
EUROPE: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
EUROPE: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
EUROPE: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
NORTH AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
EUROPE: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
ASIA PACIFIC: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
LATIN AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
NORTH AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
EUROPE: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
ASIA PACIFIC: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
LATIN AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
NORTH AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
EUROPE: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
ASIA PACIFIC: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
LATIN AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
NORTH AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
EUROPE: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
ASIA PACIFIC: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
LATIN AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE
 
 
 
 
 
 
TABLE 131
HUMAN ORGANOID MARKET FOR ONCOLOGY, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
NORTH AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
EUROPE: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
LATIN AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
NORTH AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
EUROPE: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
LATIN AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
NORTH AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
EUROPE: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
LATIN AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
NORTH AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
EUROPE: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
LATIN AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
NORTH AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
EUROPE: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
LATIN AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
NORTH AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
EUROPE: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
LATIN AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
EUROPE: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
EUROPE: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
EUROPE: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
NORTH AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
EUROPE: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
LATIN AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
NORTH AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
EUROPE: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
LATIN AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
NORTH AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
EUROPE: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
LATIN AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
NORTH AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
EUROPE: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
LATIN AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
EUROPE: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
EUROPE: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
EUROPE: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
EUROPE: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
EUROPE: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
EUROPE: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
EUROPE: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
EUROPE: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
HUMAN ORGANOIDS MARKET, BY REGION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
NORTH AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
US: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
US: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
US: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
US: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
US: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
US: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
US: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
US: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
CANADA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
CANADA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
CANADA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
CANADA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
CANADA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
CANADA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
CANADA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
CANADA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
EUROPE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
EUROPE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
EUROPE: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
GERMANY: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
GERMANY: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
GERMANY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
GERMANY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
GERMANY: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
UK: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
UK: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
UK: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
UK: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
UK: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
UK: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
UK: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
UK: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
UK: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
UK: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
FRANCE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
FRANCE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
FRANCE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
FRANCE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
FRANCE: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
ITALY: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
ITALY: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
ITALY: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
ITALY: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
ITALY: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
ITALY: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
ITALY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
ITALY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
ITALY: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
ITALY: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
SPAIN: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
SPAIN: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
SPAIN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
SPAIN: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
SPAIN: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
REST OF EUROPE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
REST OF EUROPE: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
ASIA PACIFIC: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
CHINA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
CHINA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
CHINA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
CHINA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
CHINA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
CHINA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
CHINA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
CHINA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
CHINA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
CHINA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
JAPAN: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
JAPAN: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
JAPAN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
JAPAN: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
JAPAN: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
INDIA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
INDIA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
INDIA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
INDIA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
INDIA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
INDIA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
INDIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
INDIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
INDIA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
INDIA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
SOUTH KOREA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
SOUTH KOREA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
AUSTRALIA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
AUSTRALIA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
AUSTRALIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
AUSTRALIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
AUSTRALIA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
REST OF ASIA PACIFIC: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
REST OF ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
LATIN AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
BRAZIL: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
BRAZIL: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
BRAZIL: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
BRAZIL: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
BRAZIL: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
MEXICO: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
MEXICO: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
MEXICO: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
MEXICO: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
MEXICO: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
REST OF LATIN AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
REST OF LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
MIDDLE EAST & AFRICA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
TABLE 470
HUMAN ORGANOIDS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 471
HUMAN ORGANOIDS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 472
HUMAN ORGANOIDS MARKET: OFFERING FOOTPRINT
 
 
 
 
 
 
TABLE 473
HUMAN ORGANOIDS MARKET: SOURCE FOOTPRINT
 
 
 
 
 
 
TABLE 474
HUMAN ORGANOIDS MARKET: APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 475
HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 476
HUMAN ORGANOIDS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 477
HUMAN ORGANOIDS MARKET: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 478
HUMAN ORGANOIDS MARKET: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 479
HUMAN ORGANOIDS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 480
MERCK: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 481
MERCK: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 482
MERCK: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 483
MERCK: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 484
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 485
DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 486
DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 487
SAMSUNG BIOLOGICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 488
SAMSUNG BIOLOGICS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 489
SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 490
WUXI APPTEC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 491
WUXI APPTEC: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 492
WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 493
EVOTEC SE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 494
EVOTEC SE: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 495
EVOTEC SE: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 496
CHAMPIONS ONCOLOGY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 497
CHAMPIONS ONCOLOGY: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 498
CHAMPIONS ONCOLOGY: OTHER DEVELOPMENTS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 499
ACROBIOSYSTEMS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 500
ACROBIOSYSTEMS: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 501
BIOMORGAN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 502
BIOMORGAN: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 503
BIOMORGAN: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 504
ORGANOID SCIENCES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 505
ORGANOID SCIENCES, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 506
ORGANOID SCIENCES, INC.: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 507
ORGANOID SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 508
JSR CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 509
JSR CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 510
JSR CORPORATION: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 511
THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 512
THERMO FISHER SCIENTIFIC: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 513
THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 514
THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 515
BRUKER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 516
BRUKER CORPORATION: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 517
BRUKER CORPORATION: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 518
BRUKER CORPORATION: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 519
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 520
CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 521
PHARMARON: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 522
PHARMARON: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 523
VIVOSIM LABS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 524
VIVOSIM LABS, INC.: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 525
VIVOSIM LABS, INC.: PRODUCT LAUNCHES, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 526
VIVOSIM LABS, INC.: DEALS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 527
STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 528
STEMCELL TECHNOLOGIES: PRODUCTS/SERVICES OFFERED
 
 
 
 
 
 
TABLE 529
STEMCELL TECHNOLOGIES: EXPANSIONS, JANUARY 2023–SEPTEMBER 2026
 
 
 
 
 
 
TABLE 530
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
 
 
TABLE 531
RISK ASSESSMENT: HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
HUMAN ORGANOIDS MARKET SEGMENTATION
 
 
 
 
 
 
FIGURE 2
HUMAN ORGANOIDS MARKET: YEARS CONSIDERED
 
 
 
 
 
 
FIGURE 3
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 4
GLOBAL HUMAN ORGANOID MODELS MARKET, 2023–2031
 
 
 
 
 
 
FIGURE 5
GLOBAL HUMAN ORGANOID SERVICES MARKET, 2023–2031
 
 
 
 
 
 
FIGURE 6
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 7
DISRUPTIONS INFLUENCING GROWTH OF HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
FIGURE 8
HIGH-GROWTH SEGMENTS IN HUMAN ORGANOIDS MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 9
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID MODELS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 10
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
INCREASING ADOPTION OF HUMAN ORGANOID MODELS IN DRUG DISCOVERY TO PROPEL THE HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
FIGURE 12
US AND SERVICES ACCOUNTED FOR LARGEST SHARE OF THE HUMAN ORGANOIDS MARKET IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 13
ASIA PACIFIC LIKELY TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 14
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 15
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 16
HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 17
GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 18
GLOBAL HUMAN ORGANOID MODELS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 19
GLOBAL HUMAN ORGANOIDS SERVICES MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 20
GLOBAL HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 21
HUMAN ORGANOIDS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
FIGURE 22
TOP APPLICANTS & OWNERS (COMPANIES) FOR HUMAN ORGANOIDS PATENTS, 2015–DECEMBER 2025
 
 
 
 
 
 
FIGURE 23
IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET
 
 
 
 
 
 
FIGURE 24
ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY OFFERING
 
 
 
 
 
 
FIGURE 25
ILLUSTRATIVE BUYING PRIORITIES, BY END USER
 
 
 
 
 
 
FIGURE 26
NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2023–2025)
 
 
 
 
 
 
FIGURE 29
MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2025)
 
 
 
 
 
 
FIGURE 30
HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 31
HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 32
HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 33
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 34
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 35
HUMAN ORGANOIDS MARKET: BRAND COMPARISON
 
 
 
 
 
 
FIGURE 36
MERCK: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 37
DANAHER CORPORATION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 38
SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 39
WUXI APPTEC: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 40
EVOTEC SE: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 41
ACROBIOSYSTEMS: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 42
ORGANOID SCIENCES, INC.: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 43
THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 44
BRUKER CORPORATION: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 45
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 46
PHARMARON: COMPANY SNAPSHOT
 
 
 
 
 
 
FIGURE 47
HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY
 
 
 
 
 
 
FIGURE 48
HUMAN OGRANOIDS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
FIGURE 49
GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025
 
 
 
 
 
 
FIGURE 50
HUMAN ORGANOIDS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
 
 
 
 
 
 
FIGURE 51
HUMAN ORGANOIDS MARKET: INSIGHTS FROM PRIMARIES
 
 
 
 
 
 
FIGURE 52
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 53
HUMAN ORGANOIDS MARKET: CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 54
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

Methodology

The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

BREAKDOWN OF PRIMARY PARTICIPANTS:

Human Organoids Market
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the human organoids market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Human Organoids Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.

Key Stakeholders

  • Senior Management
    • End User
    • Finance/Procurement Department
    • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global human organoids market by product, source, usability, culture method, disease area, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall human organoids market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, the Middle East & Africa, and Latin America
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence.

Available customizations:

MarketsandMarkets offers the following customizations for this market report.

Country Information

  • Additional country-level analysis of the human organoids market

Company profiles

  • Additional five company profiles of players operating in the human organoids market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the human organoids market

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Human Organoids Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Human Organoids Market

DMCA.com Protection Status
popup img